UbiVac

UbiVac is a private, clinical-stage biotech focused on disrupting cancer treatment with its 'Dark Matter' immunotherapy platform, which targets non-mutated, shared neoantigens derived from the 'Dark Genome.' The company's lead program, DPV-001, has demonstrated compelling clinical results, including a median overall survival of 25.5 months in PD-1-naïve patients, doubling the standard-of-care benchmark. With in-house GMP manufacturing and a discovery engine aimed at identifying novel targets for multiple therapeutic modalities, UbiVac is positioned to advance a potential universal cancer vaccine while mining its platform for new drug discovery opportunities. The company is led by renowned immunotherapy expert Dr. Bernard A. Fox and is closely aligned with the Earle A. Chiles Research Institute.

Platform for developing off-the-shelf cancer vaccines targeting non-mutated, shared neoantigens derived from the 'Dark Genome' (short-lived proteins/SLiPs). Includes in-house GMP manufacturing and a discovery engine using AI/ML to identify novel targets for vaccines, ADCs, CAR-T/NK, and TCR therapies.

UbiVac competes in the rapidly evolving cancer vaccine and neoantigen therapy space, facing competition from both companies developing personalized neoantigen vaccines (e.g., BioNTech, Moderna) and those pursuing shared antigen approaches. Its first-mover focus on 'Dark Genome'-derived antigens is a key differentiator, but it must demonstrate superior efficacy to established checkpoint inhibitors and other combination regimens.